1-6 of 6
Robert Henderson
Close
Sort by
Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy
Journal: Blood
Blood (2021) 138 (Supplement 1): 2756.
https://doi.org/10.1182/blood-2021-145530
Published: 2021
Journal Articles

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

John Daly, MSc, Subhashis Sarkar, PhD, Alessandro Natoni, PhD, Robert Henderson, MB BCh, Dawn Swan, Mattias Carlsten, MD PhD, Michael E O'Dwyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 138.
https://doi.org/10.1182/blood-2019-126613
Published: 2019
Journal Articles

Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity

Robert Henderson, MB BCh, Lucy Kirkham-McCarthy, MSc, Dawn Swan, BM BCh, Michael E O'Dwyer, MD, Alessandro Natoni, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4453.
https://doi.org/10.1182/blood-2018-99-116747
Published: 2018
Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3242.
https://doi.org/10.1182/blood-2018-99-112375
Published: 2018
Journal Articles

CD38 low Natural Killer Cells Transiently Expressing CD16 F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide

Subhashis Sarkar, PhD, Sachin Chauhan, MSc, Arwen Stikvoort, PhD, Alessandro Natoni, PhD, John Daly, MSc, Robert Henderson, MB BCh, Tuna Mutis, PhD, Michael E O'Dwyer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3199.
https://doi.org/10.1182/blood-2018-99-118926
Published: 2018
Journal Articles

Turning the Heat up a Notch in Biclonal Lymphoproliferative Disorders

Helen Fogarty, Anita Dowling, David O'Brien, Christopher Laurence Bacon, Patrick Thornton, Brian Hennessy, MD MRCPI, FRCPath, Hilary M O'Leary, FRCPath, Gerard Crotty, Robert Henderson, James Nolan, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD, Fiona M Quinn, PhD
Journal: Blood
Blood (2016) 128 (22): 5569.
https://doi.org/10.1182/blood.V128.22.5569.5569
Published: 2016